ACT Brief: Evinova Expands AI Partnerships, CTPM Role Evolves, and FDA Pressure Builds on GLP-1 Market

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• Evinova has entered a new phase of growth through strategic collaborations with AstraZeneca, Astellas Pharma, and Bristol Myers Squibb aimed at scaling its AI-native platform across global development. The model centers on opt-in data sharing to generate benchmarks and improve trial execution, with early deployments already showing measurable reductions in study costs driven by more efficient protocol design and fewer downstream amendments.
• A new contributor analysis on ACT highlights how the clinical trial project manager role is expanding as digital tools, regulatory shifts, and operational complexity reshape trial execution. Leaders are now expected to combine traditional project oversight with technical fluency and adaptive decision-making, as organizations place greater emphasis on real-time data, distributed teams, and continuous change management to maintain timelines and performance.
• In a new video interview on Pharm Exec, Jay Bregman, CEO and co-founder of Andel, warned that increased scrutiny from the FDA on non-approved GLP-1 products could significantly disrupt the obesity and diabetes market. The expected crackdown on compounded therapies may force patients to seek alternative access pathways, while also reinforcing incentives for manufacturers to prioritize fully approved, regulated treatments.

That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.